Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ

Hope Center for Neurological Disorders, Washington University in St. Louis, San Luis, Missouri, United States
Journal of Biological Chemistry (Impact Factor: 4.57). 09/2006; 281(34):24566-74. DOI: 10.1074/jbc.M602440200
Source: PubMed


The pathological hallmark of Alzheimer disease is the senile plaque principally composed of tightly aggregated amyloid-beta fibrils (fAbeta), which are thought to be resistant to degradation and clearance. In this study, we explored whether proteases capable of degrading soluble Abeta (sAbeta) could degrade fAbeta as well. We demonstrate that matrix metalloproteinase-9 (MMP-9) can degrade fAbeta and that this ability is not shared by other sAbeta-degrading enzymes examined, including endothelin-converting enzyme, insulin-degrading enzyme, and neprilysin. fAbeta was decreased in samples incubated with MMP-9 compared with other proteases, assessed using thioflavin-T. Furthermore, fAbeta breakdown with MMP-9 but not with other proteases was demonstrated by transmission electron microscopy. Proteolytic digests of purified fAbeta were analyzed with matrix-assisted laser desorption ionization time-of-flight mass spectrometry to identify sites of Abeta that are cleaved during its degradation. Only MMP-9 digests contained fragments (Abeta(1-20) and Abeta(1-30)) from fAbeta(1-42) substrate; the corresponding cleavage sites are thought to be important for beta-pleated sheet formation. To determine whether MMP-9 can degrade plaques formed in vivo, fresh brain slices from aged APP/PS1 mice were incubated with proteases. MMP-9 digestion resulted in a decrease in thioflavin-S (ThS) staining. Consistent with a role for endogenous MMP-9 in this process in vivo, MMP-9 immunoreactivity was detected in astrocytes surrounding amyloid plaques in the brains of aged APP/PS1 and APPsw mice, and increased MMP activity was selectively observed in compact ThS-positive plaques. These findings suggest that MMP-9 can degrade fAbeta and may contribute to ongoing clearance of plaques from amyloid-laden brains.

Download full-text


Available from: Qingli Xiao, May 27, 2015
  • Source
    • "Neuronal survival was assessed by MAP-2–specific immunofluorescence staining, as described previously (Mizuno et al., 2008, 2011; Yan et al., 2006). Viable neurons stained strongly with anti–MAP-2 antibodies, whereas damaged neurons showed much weaker staining. "

    Full-text · Article · Sep 2015 · Clinical and Experimental Neuroimmunology
  • Source
    • "Aβ-activated microglia release a wide variety of neurotoxic molecules including proinflammatory cytokines (Griffin, 2006), reactive oxygen species (Reddy et al., 2009), and complement proteins (Bonifati and Kishore, 2007), which contribute to the neurodegeneration in AD. On the other hand, microglia have beneficial effects against AD as a result of neurotrophic agent secretion and clearing Aβ by phagocytosis (Mizuno et al., 2004; Yan et al., 2006). In addition, in vitro experiments strongly suggest a role for microglia in phagocytic clearance of Aβ. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study was to evaluate the therapeutic potential of human induced pluripotent stem (iPS) cell-derived macrophage-like cells for Alzheimer’s disease (AD). In previous studies, we established the technology to generate macrophage-like myeloid lineage cells with proliferating capacity from human iPS cells, and we designated the cells iPS-ML. iPS-ML reduced the level of Aβ added into the culture medium, and the culture supernatant of iPS-ML alleviated the neurotoxicity of Aβ. We generated iPS-ML expressing the Fc-receptor-fused form of a single chain antibody specific to Aβ. In addition, we made iPS-ML expressing Neprilysin-2 (NEP2), which is a protease with Aβ-degrading activity. In vitro, expression of NEP2 but not anti-Aβ scFv enhanced the effect to reduce the level of soluble Aβ oligomer in the culture medium and to alleviate the neurotoxicity of Aβ. To analyze the effect of iPS-ML expressing NEP2 (iPS-ML/NEP2) in vivo, we intracerebrally administered the iPS-ML/NEP2 to 5XFAD mice, which is a mouse model of AD. We observed significant reduction in the level of Aβ in the brain interstitial fluid following administration of iPS-ML/NEP2. These results suggested that iPS-ML/NEP2 may be a potential therapeutic agent in the treatment of AD.
    Full-text · Article · Oct 2014 · Stem Cell Research
  • Source
    • "By combining in situ zymography and MMP inhibition with GM6001, we further confirmed MMP-dependent gelatinolytic activity especially in amyloid plaques. Since MMP-9 and MT1-MMP immunostaining were particularly prominent in amyloid plaques, it is possible that they contribute to gelatinolysis in a significant manner, which would be consistent with the singular ability of both MMPs to degrade fibrillar Aβ (Yan et al., 2006; Liao and Van Nostrand, 2010). The pathophysiological consequences of amyloid plaque degradation by these MMPs have not been investigated yet, and will likely depend on the cytotoxicity of the potentially released breakdown products (e.g., oligomers). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Matrix metalloproteinases (MMPs) are pleiotropic endopeptidases involved in a variety of neurodegenerative/neuroinflammatory processes through their interactions with a large number of substrates. Among those, the amyloid precursor protein (APP) and the beta amyloid peptide (Aβ) are largely associated with the development of Alzheimer's disease (AD). However, the regulation and potential contribution of MMPs to AD remains unclear. In this study, we investigated the evolution of the expression of MMP-2, MMP-9, and membrane-type 1-MMP (MT1-MMP) in the hippocampus at different stages of the pathology (asymptomatic, prodromal-like and symptomatic) in the 5xFAD transgenic mouse AD model. In parallel we also followed the expression of functionally associated factors. Overall, the expression of MMP-2, MMP-9, and MT1-MMP was upregulated concomitantly with the tissue inhibitor of MMPs-1 (TIMP-1) and several markers of inflammatory/glial response. The three MMPs exhibited age-and cell-dependent upregulation of their expression, with MMP-2 and MMP-9 being primarily located to astrocytes, and MT1-MMP to neurons. MMP-9 and MT1-MMP were also prominently present in amyloid plaques. The levels of active MT1-MMP were highly upregulated in membrane-enriched fractions of hippocampus at 6 months of age (symptomatic phase), when the levels of APP, its metabolites APP C-terminal fragments (CTFs), and Aβ trimers were the highest. Overexpression of MT1-MMP in HEK cells carrying the human APP Swedish mutation (HEKswe) strongly increased β-secretase derived C-terminal APP fragment (C99) and Aβ levels, whereas MMP-2 overexpression nearly abolished Aβ production without affecting C99. Our data consolidate the emerging idea of a regulatory interplay between MMPs and the APP/Aβ system, and demonstrate for the first time the pro-amyloidogenic features of MT1-MMP. Further investigation will be justified to evaluate this MMP as a novel potential therapeutic target in AD.
    Full-text · Article · Sep 2014 · Frontiers in Aging Neuroscience
Show more